Cardiovascular — Selling, general and administrative expenses
Boston Scientific Cardiovascular — Selling, general and administrative expenses increased by 7.6% to $990.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 18.0%, from $839.00M to $990.00M. Over 3 years (FY 2022 to FY 2025), Cardiovascular — Selling, general and administrative expenses shows an upward trend with a 14.5% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
High spending may be necessary for market penetration, but excessive growth relative to revenue can signal inefficiency.
Detailed definition
Represents the operating costs incurred to support the Cardiovascular segment, including sales force compensation, marke...
Peer comparison
Standard SG&A expense reporting for business segments.
bsx_segment_cardiovascular_selling_general_and_administrative_expensesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $613.50M | $613.50M | $613.50M | $613.50M | $687.25M | $687.25M | $687.25M | $687.25M | $740.00M | $796.00M | $791.00M | $839.00M | $867.00M | $908.00M | $920.00M | $990.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +12.0% | +0.0% | +0.0% | +0.0% | +7.7% | +7.6% | -0.6% | +6.1% | +3.3% | +4.7% | +1.3% | +7.6% |
| YoY Change | — | — | — | — | +12.0% | +12.0% | +12.0% | +12.0% | +7.7% | +15.8% | +15.1% | +22.1% | +17.2% | +14.1% | +16.3% | +18.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Boston Scientific's cardiovascular — selling, general and administrative expenses?
- Boston Scientific (BSX) reported cardiovascular — selling, general and administrative expenses of $990.00M in Q4 2025.
- How has Boston Scientific's cardiovascular — selling, general and administrative expenses changed year-over-year?
- Boston Scientific's cardiovascular — selling, general and administrative expenses increased by 18.0% year-over-year, from $839.00M to $990.00M.
- What is the long-term trend for Boston Scientific's cardiovascular — selling, general and administrative expenses?
- Over 3 years (2022 to 2025), Boston Scientific's cardiovascular — selling, general and administrative expenses has grown at a 14.5% compound annual growth rate (CAGR), from $2.45B to $3.69B.
- What does cardiovascular — selling, general and administrative expenses mean?
- The total operating costs for sales, marketing, and administration in the Cardiovascular segment.